Transcutaneous Carbon Dioxide Induces Mitochondrial Apoptosis and Suppresses Metastasis of Oral Squamous Cell Carcinoma In Vivo

Daisuke Takeda¹, Takumi Hasegawa¹*, Takeshi Ueha², Yusuke Imai³, Akiko Sakakibara¹, Masaya Minoda³, Teruya Kawamoto³, Tsutomu Minamikawa¹, Yasuyuki Shibuya¹, Toshihiro Akisue³, Yoshitada Sakai⁴, Masahiro Kurosaka³, Takahide Komori¹

¹ Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ² NeoChemir, Kobe, Japan, ³ Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴ Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

Abstract

Squamous cell carcinoma (SCC) is the main histological type of oral cancer. Its growth rate and incidence of metastasis to regional lymph nodes is influenced by various factors, including hypoxic conditions. We have previously reported that transcutaneous CO₂ induces mitochondrial apoptosis and decreases lung metastasis by reoxygenating sarcoma cells. However, previous studies have not determined the sequential mechanism by which transcutaneous CO₂ suppresses growth of epithelial tumors, including SCCs. Moreover, there is no report that transcutaneous CO₂ suppresses lymphogenous metastasis using human cell lines xenografts. In this study, we examined the effects of transcutaneous CO₂ on cancer apoptosis and lymphogenous metastasis using human SCC xenografts. Our results showed that transcutaneous CO₂ affects expressions of PGC-1α and TFAM and protein levels of cleavage products of caspase-3, caspase-9, and PARP, which relates mitochondrial apoptosis. They also showed that transcutaneous CO₂ significantly inhibits SCC tumor growth and affects expressions of HIF-1α, VEGF, MMP-2 and MMP-9, which play essential roles in tumor angiogenesis, invasion, and metastasis. In conclusion, transcutaneous CO₂ suppressed tumor growth, increased mitochondrial apoptosis and decreased the number of lymph node metastasis in human SCC by decreasing intra-tumoral hypoxia and suppressing metastatic potential with no observable effect in vivo. Our findings indicate that transcutaneous CO₂ could be a novel therapeutic tool for treating human SCC.

Introduction

Squamous cell carcinoma (SCC), the main histological type of oral cancer, comprises over 90% of all oral malignancies. SCCs grow rapidly and readily metastasize to the regional lymph nodes [1]. Lymph node metastasis is a well-established negative prognostic indicator in the treatment of squamous cell carcinoma of the head and neck [2]. Considerable efforts have been made to control both metastases and primary tumors in patients with oral cancer [3].

Hypoxia, a common feature of malignant tumors, occurs in numerous solid tumors [4]. Hypoxia inducible factors (HIFs) depends directly on tumor hypoxia and, in human malignancies, HIFs critically affect resistance to chemo- and radiation therapy and are associated with histological grade, stage, and recurrence [5]. Overexpression of HIF-1α, an oxygen-dependent α subunit of HIF, has been associated with tumor cell growth, lymph node metastasis and survival in head and neck tumors [6–8]. HIF-1α mediates the adaptation of cancer cells to hypoxic environments by controlling expression of hundreds of genes, including vascular endothelial growth factor (VEGF). HIF-1α is also strongly induced under hypoxic conditions, and activates transcription of genes involved in metastasis, including matrix metalloproteinases (MMPs). Increased expression of certain MMPs correlates with tumor growth, invasion, and poor prognosis in patients with malignancies. Among the MMP subtypes, MMP-2 and MMP-9 are widely reported as crucial to the invasive and metastatic potentials of various malignancies. Although decreasing activity of HIF-1α and/or MMPs by reducing tumor hypoxia could be an effective strategy in cancer treatment, there is currently no effective way of achieving reduction of hypoxia in tumors [5,9].

The benefits of carbonated spa (carbon dioxide; CO₂ therapy) have long been known in Europe. CO₂ therapy is believed to an effective treatment for cardiac diseases and skin problems [10,11]. The therapeutic effects of CO₂ are mediated by an increase in blood flow and microcirculation, nitric oxide-dependent neocapillary formation, and an increase of partial pressure of O₂ in the local tissue known as the Bohr effect. The Bohr effect is...
represented by a rightward shift of the O₂ hemoglobin dissociation curve with increasing pCO₂ or decreasing pH [12]. We have previously demonstrated in vivo that transcutaneous CO₂ leads to increased O₂ release from red blood cells, causing an "Artificial Bohr Effect" [12], and up-regulates O₂ pressure, with increased expression of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) and the number of mitochondria in treated skeletal muscle tissue [13]. We have also shown that, in human malignant fibrous histiocytoma (MFH) xenografts, transcutaneous CO₂ decreases expression of HIF-1α and induces mitochondrial apoptosis, in turn increasing PGC-1α and mitochondrial transcription factor A (TFAM) [9,14]. In osteosarcoma, transcutaneous CO₂ also decreases the incidence of hematogenous metastases to the lungs by reducing hypoxia [5].

Previous studies have not determined the sequential mechanism by which transcutaneous CO₂ suppresses growth of epithelial tumors, including SCCs. Moreover, there is no report that transcutaneous CO₂ suppresses lymphogenous metastasis using human cancer cell xenografts. MFH and osteosarcoma mainly metastasize hematogenously, however both hematogenous and lymphogenous metastases occur from SCCs. Lymphogenous metastasis, rather than hematogenous metastasis, is often observed in SCCs in clinical settings. Here, we suggest that transcutaneous CO₂ may reduce hypoxia and induce mitochondrial pathways in SCC. In this study, we investigated whether transcutaneous CO₂ can induce tumor cell apoptosis and suppress lymphogenous metastatic spread to the regional lymph nodes in human SCC.

**Materials and Methods**

**Cell Culture**

The oral cancer cell line used in this study, HSC-3, was obtained from the Health Science Research Resources Bank (Osaka, Japan). HSC-3 cells were established from a metastatic deposit of poorly differentiated SCC of the tongue in a mid-internal jugular lymph node from a 64 year old man [15]. HSC-3 cells in Eagle’s minimum essential medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 1000 units/mL penicillin/streptomycin solution (Sigma-Aldrich) were routinely cultured in an incubator in 5% CO₂ at 37°C. Trypsin (0.25%) and ethylenediaminetetraacetic acid (0.02%; Sigma-Aldrich) solution was used to isolate cells for subculture, as previously described [16].

**Animal models**

Male athymic BALB/cAJcl-nu/nu nude mice aged 7 weeks were obtained from CLEA Japan (Tokyo, Japan). The animals were maintained under pathogen-free conditions, in accordance with institutional principles. All animal experiments were performed in accordance with the Guidelines for Animal Experimentation at Kobe University Animal Experimentation Regulations (Permission number: P120602) and were approved by the Institutional Animal Care and Use Committee. HSC-3 cells (2.0×10⁶ cells in 500 μL phosphate buffered saline [PBS]) were injected subcutaneously into the backs of the mice, as previously described [17].

**Transcutaneous CO₂ treatment**

Transcutaneous CO₂ was administered as previously described. Briefly, the area of skin around the implanted tumor was covered with CO₂ absorption-enhancing hydrogel (CO₂ hydrogel). This area was then sealed with a polyethylene bag and 100% CO₂ gas pumped into the bag (Fig. 1). Each treatment was performed for 20 min. Control animals were treated similarly, room air replacing the CO₂ [5,9,13,14].

**In vivo HSC-3 tumor studies**

Sixteen mice were randomly divided into two groups: a CO₂-treated group (n = 8) and a control group (n = 8). Treatment commenced 7 days after HSC-3 cell implantation and was performed twice a week for 3 weeks. Tumor volume and body weight were monitored twice weekly until the end of the treatment. Tumor volume was calculated as previously described according to the formula \( V = \frac{\pi}{6} a^2 \times b \), where a and b represent the shorter and longer diameters of the tumor, respectively [5,9,14].

**Surgical procedure**

The treatment was completed 4 weeks after commencing treatment, and 24 h after the end of treatment, mice were weighed and sacrificed by intraperitoneal injection of an overdose pentobarbital (Kyoritsuseiyaku, Tokyo, Japan) and tumors and bilateral axillary lymph nodes were removed. Immediately after
dissection, single cell suspensions were processed from half of the tumor, and RNA and protein were extracted. The other half of the tumor was formalin-fixed and paraffin-embedded for staining. Serial 10 µm thick transverse sections were prepared from each block.

**Apoptosis analysis: determination of the relative mitochondrial copy number**

Genomic DNA was isolated from 10 µg of tumor using a GenElute Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich). Mitochondrial DNA (mtDNA) content relative to PGC-1α and TFAM gene was measured using real-time polymerase chain reaction (PCR). The sequences of primer pairs specifically designed to amplify the entire D-loop of mtDNA were as follows: forward (5'-CTC CAC CAT TAG CAC CCA AAG-3') and reverse (5'-GTG TGA TGC GGC GCT CTA AAC-3') (D-loop, 1232 bp) and for nucleotide DNA-encoded internal control gene β-actin: forward (5'-ATC ATG TTT GAG ACC ATG CTC TTG GAG ACC TAC-3') and reverse (5'-CAT TCT TGG GTC GAA GTC CA-3') [beta-actin, 310 bp] [10]. The PCR cycling conditions were 15 min at 95°C, followed by 40 cycles of 30 sec at 95°C, 20 sec at 60°C and 2 min at 72°C.

**Analysis of mRNA expression of apoptotic and metastatic factors: total RNA extraction and reverse transcription**

Total RNA was extracted from tumors using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNA was synthesized (300 ng total RNA) using a High Capacity cDNA Transcription Kit (Applied Biosystems, Foster City, CA, USA).

**Quantitative real-time PCR**

The mRNA expression of β-actin, PGC-1α, TFAM, VEGF, MMP-2 and MMP-9 were analyzed by quantitative real-time PCR. Quantification of mRNA transcription was performed using an Applied Biosystems StepOne Real-Time PCR System (Applied Biosystems). Real-Time PCR reactions (20 µL) contained 0.5 µM forward primer, 0.5 µM reverse primer, and 1 µL of cDNA template from RT reaction, and 10 µL (2×) master mix for Power SYBR green master mix (Applied Biosystems). Reaction conditions included 10 min at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. The level of each target gene was normalized to β-actin level and expressed relative to the levels of the control group (ΔΔCT methods; Applied Biosystems).

**Design of primers**

Primers for β-actin, the housekeeping gene, were designed as follows: forward (5'-GAT GAG ATT GGC ATG GCT TT-3') and reverse (5'-CAG CTT TAC CGT GGC AGT TT-3'), for PGC-1α: forward (5'-GCG AGA AGG CAA TTG AAG AG-3') and reverse (5'-TCA AAA CGG TCG CTC AAG TG-3'), for TFAM: forward (5'-GTG TAT TGG CAG GAC GCT CT-3') and reverse (5'-CAG ATT CTG CAG GGA AAC G-3'), for VEGF: forward (5'-GAG CCT TGC TCT CCT GCT GT-3') and reverse (5'-CAG GAG GCT GCT GTC ATG TG-3'), for MMP-2: forward (5'-ACA GCA GGT GCT ACG GCA TG-3') and reverse (5'-TCC TCG TGG ACA ACA GAC AC-3') and for MMP-9: forward (5'-TCT TCC TGG GAG GAC TAA GA-3') and reverse (5'-ATT TCG ACT CTA GCA TCG-3'). All primers were purchased from Invitrogen (Carlsbad, CA, USA).

**Western immunoblot analysis**

Cell lysates were prepared from implanted tumor tissues using a whole cell lysis buffer supplemented with Halt protease and phosphatase inhibitor cocktail (Mammalian Protein Extraction Reagent; Thermo Scientific, Rockford, IL, USA). Protein samples were processed using standard western immunoblotting procedures. Membranes were incubated overnight at 4°C with the following antibodies in Can Get Signal Immunoreaction Enhancer Solution 1 (Toyobo, Osaka, Japan): anti-human cleaved caspase-3 antibody (1:500) (Cell Signaling Technology, Danvers, MA, USA), anti-human cleaved caspase-9 antibody (1:500) (Cell Signaling Technology), anti-human poly-ADP-ribose polymerase-1 (PARP) antibody (1:500) (Cell Signaling Technology), and anti-human α tubulin antibody (1:5000) (Sigma-Aldrich). After washing, the membranes were incubated with the appropriate secondary antibody conjugated to horseradish peroxidase (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) in Can Get Signal Immunoreaction Enhancer Solution 2, and exposed with ECL Prime Plus western blotting detection system reagent (GE Healthcare Bio-Sciences). The signals were detected using a Chemilumino analyzer LAS-3000 mini (Fujifilm, Tokyo, Japan) [9].

**Fluorescence activated cell scanning (FACS) assay**

DNA fragmentation was evaluated using an APO-DIRECT Kit according to the manufacturer’s protocol (BD Pharmingen, Franklin Lakes, NJ, USA). Briefly, the implanted tumors were excised, minced and filtered through a cell strainer (BD Falcon, Bedford, MA, USA) to obtain single cell suspensions. Erythrocytes were lysed in BD Pharm Lyse Lysing Buffer (BD Pharmingen) and the remaining cells pellet and resuspended in PBS. Single cell suspensions were fixed with 1% (v/v) paraformaldehyde and resuspended in 70% (v/v) ice cold ethanol at a concentration of 1 × 10^6 cells/mL. Each cell pellet was resuspended in 51.0 µL of DNA Labeling Solution (Reaction Buffer, 10.0 µL; terminal deoxynucleotidyl transferase enzyme, 0.75 µL; fluorescein isothiocyanate (FITC) deoxyuridine triphosphate (dUTP), 8.0 µL; distilled H2O2, 32.5 µL and incubated for 60 min at 37°C. FITC dUTP-labeled cells were analyzed by flow cytometry with a 488 nm argon laser (FACS Calibur, BD Pharmingen) [14].

**Immunohistochemical staining**

Formalin-fixed and paraffin-embedded tumor sections were pretreated with citrate buffer for 40 min at 95°C, quenched with 0.05% H2O2, and incubated overnight at 4°C with the following primary antibodies in Can Get Signal Immunostain Solution A (Toyobo): rabbit anti-human VEGF polyclonal antibody (1:50) (Abcam, Cambridge, UK), rabbit anti-human HIF-1α antibody (1:50) (Cell Signaling Technology), mouse anti-human MMP-2 antibody (1:100) (Novocastra Laboratories, New-castle, UK) and mouse anti-human MMP-9 antibody (1:100) (Novocastra Laboratories). Following this treatment, sections were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG polyclonal antibody (Nichirei Bioscience, Tokyo, Japan) for 30 min at room temperature. Signals were developed as a brown reaction product using peroxidase substrate 3',3'-diaminobenzidine (Ni- chirei Bioscience). The sections were counterstained with hematoxylin and examined with a BZ-8000 confocal microscope (Keyence, Osaka, Japan) [5].

**Detection of micro metastases in the axillary lymph nodes**

We evaluated the existence of lymphogenous metastasis in mouse, all of axillary lymph nodes were dissected. The formalin-fixed and paraffin-embedded lymph node sections were stained with hematoxylin and eosin.
Figure 2. The effect of transcutaneous \( \text{CO}_2 \) on HSC-3 tumor growth. Tumor growth (A) and body weight (B) was monitored for 4 weeks in the \( \text{CO}_2 \)-treated and control groups (*\( p < 0.05 \)).
doi:10.1371/journal.pone.0100530.g002

Figure 3. The effect of transcutaneous \( \text{CO}_2 \) on HSC-3 cell apoptotic pathway. (A) The mRNA expressions of PGC-1\( \alpha \) and TFAM gene were evaluated using real-time PCR (*\( p < 0.05 \)). (B) Mitochondrial DNA (mtDNA) content was also measured; differences were not statically significant. (C) Immunoblot analysis of expressions of the cleavage products of caspase-3, caspase-9 and PARP. \( \beta \)-actin was used as an endogenous loading control. (D) At the end of experiment, the numbers of apoptotic cells in tumors of both groups were assessed by FACS.
doi:10.1371/journal.pone.0100530.g003
Detection of metastases by PCR analysis for the human \(\beta\)-globin gene

Genomic DNA was extracted from axillary lymph nodes using SepaGene (EIDIA, Tokyo, Japan) according to the protocol recommended by the manufacturer. Two sets of primers for the human \(\beta\)-globin gene were designed (human \(\beta\)-globin Primer Set; Takara Bio, Shiga, Japan). The first primers were designed outside the region amplified by the second primer. The outer primers were designed as follows: GH20 (forward) (5'-GAA GAG CCA AGG ACA GGT AC-3') and GH21 (reverse) (5'-GGA AAA TAG ACC AAT AGG CAG-3') (amplified size of DNA: 408 bp); and the inner primers, KM29 (forward) (5'-GGT TGG CCA ATC TAC TCC CAG G-3') and KM38 (reverse) (5'-TGG TCT CCT TAA ACC TGT CTT G-3') (262 bp). The PCR reaction contents were as previously described using TaKaRa Taq (Takara Bio). The PCR conditions for the first reaction were 30 cycles of denaturing at 94°C for 1 min, annealing at 55°C for 2 min, and extension at 72°C for 2 min, according to the protocol recommended by the manufacturer. In the second step, the first PCR product was removed and reamplified using two sets of overlapping inner primers. Conditions for the second PCR were the same as for the first reaction. The PCR product was electrophoresed in a 2.0% agarose gel containing 0.5 \(\mu\)g/mL ethidium bromide [19–22].

Statistical analysis

Data are presented as the mean values ± standard error. The results of the two groups were analyzed using the Mann-Whitney U-test. The level of statistical significance was set at \(P<0.05\).

Results

Transcutaneous application of CO\(_2\) suppresses SCC growth by inducing apoptosis

We evaluated the effect of transcutaneous CO\(_2\) on SCC cell growth. In the CO\(_2\)-treated group, we found a significant decrease in tumor volume after 14 days (\(P<0.05\), Fig. 2A). At the end of the experiment, tumor volume had decreased by significantly more in the CO\(_2\)-treated (67.9±24.1 mm\(^3\)) than in the control group (376.1±104.1 mm\(^3\), \(P<0.05\), Fig. 2A). Mean body weight was slightly less in the CO\(_2\)-treated than in the control group; however, this difference was not significant (Fig. 2B). Quantitative real-time PCR showed that mRNA expressions of PGC-1\(\alpha\) and TFAM were significantly higher in the CO\(_2\)-treated than in the control group (\(P<0.05\), Fig. 3A). Mitochondrial copy number tended to be greater in the CO\(_2\)-treated group; however, this difference was not significant (Fig. 3B). Immunoblot analysis showed greater amounts of cleavage products of caspase-3, caspase-9 and PARP in the CO\(_2\)-treated than in the control group (Fig. 3C). FACS analysis showed that apoptotic cells were more numerous in the CO\(_2\)-treated than in the control group (Fig. 3D).

Transcutaneous CO\(_2\) significantly reduces intra-tumoral hypoxia and suppresses the potential to metastasize to lymph nodes

Finally, we evaluated the effects of transcutaneous CO\(_2\) on tumor hypoxia and development of lymph nodes metastases in SCC. In implanted tumors, quantitative real-time PCR showed that mRNA expressions of VEGF, MMP-2 and MMP-9 were significantly lower in the CO\(_2\)-treated than in the control group (\(P<0.05\), Fig. 4A). HIF-1\(\alpha\), VEGF, MMP-2 and MMP-9 were barely detectable by immunohistochemical positive staining in the CO\(_2\)-treated tumors, but were strongly positive in the control group (Fig. 4B).

Transcutaneous CO\(_2\) significantly suppresses lymph node metastasis

We identified micrometastatic lesions, so called cancroid pearls, in the control group’s axillary lymph nodes, but not in those of the CO\(_2\)-treated group (Fig. 5A). On PCR analysis, positive reactions with the human \(\beta\)-globin gene were observed in 5 of 8 mice in the control group (62.5%), but in only 1 of 8 mice in the CO\(_2\)-treated group (12.5%) (Fig. 5B, C).

Discussion

The prognosis of patients with advanced SCC remains poor because it is often hard to control lymph node metastasis [23]. Therefore, to improve prognosis, it is important not only to suppress tumor growth at the primary site but also to prevent lymph node metastasis. Surgical excision is the most effective therapy for SCC patients; however, resection of advanced disease can have serious cosmetic and functional consequences, making it...
difficult for these patients to be rehabilitated in a social sense. On the other hand, although chemotherapy and radiotherapy may cause less dysfunction, these therapies are often ineffective and associated with a poor prognosis because of local recurrence and metastasis [24]. Furthermore, when oral cancer has metastasized to lung, bone, or other distant organs, it is difficult to both achieve radical cure and maintain quality of life [16]. Although various combinations of surgery, chemo-radiotherapy and other treatments have been studied, there are numerous problems regarding effectiveness and adverse effects; further research is needed.

Hypoxia is common in solid tumors, including SCCs, and can increase the invasiveness and metastatic ability of tumor cells [25]. A hypoxic microenvironment induces various molecular pathways that allow tumor cells to become resistant to chemotherapy and radiotherapy. For example, expression of the multidrug resistance (MDR1) gene is dependent on hypoxia. This gene produces a protein that is associated with tumor resistance to chemotherapeutic agents [26]. In human oral SCC, a hypoxic microenvironment plays an important role in expressions of HIF-1α and MMPs and in proliferative activity of tumor cells [27]. The transcriptional factor HIF-1α, one of the key regulators of oxygen homeostasis, is an important mediator of solid tumor development in vivo because it promotes angiogenesis and inhibits cancer apoptosis. Overexpression of HIF-1α inhibits reduction of mitochondrial membrane potential by caspase-9 and caspase-3 [28]. HIF-1α also regulates VEGF expression, which has been shown to be a key mechanism in the abnormal and excessive angiogenesis and metastasis induced by hypoxia in malignant cells [9,29,30]. In hypoxic culture conditions, human SCC cell lines increase production of VEGF [31]. Because tumor angiogenesis plays an important role in local growth, enhancing cell motility, promoting metastasis and inhibition of apoptosis in oral cancer, inhibiting angiogenesis is an effective means in treating oral cancer [16]. The expression of VEGF has been shown to be strongly correlated with lymphangiogenesis and lymph node metastasis in oral SCC [32]. Additionally, the degree of VEGF expression has been reported.

Figure 5. The effect of transcutaneous CO₂ on metastasis of HSC-3 to the regional lymph nodes. (A) Detection of micrometastases in the axillary lymph nodes by hematoxylin and eosin staining. (B, C) Human β-globin gene expression in the axillary lymph nodes was assessed by PCR analysis to detect metastasis.
doi:10.1371/journal.pone.0100530.g005
as the most significant predictor of poor prognosis in oral and oropharyngeal SCCs [33]. HIF-1α also regulates MMPs that degrade extracellular matrix components and promote invasion [34]. Additionally, overexpression of MMPs has been shown to promote invasion and metastasis of various tumors, including oral cancer [35-38]. In oral SCC, the degree of activation of MMP-2 and MMP-9 is significantly higher in malignant tissues of patients with lymph node metastasis than in those without lymph node metastasis [39]. Therefore, improvement in hypoxic conditions may control tumor progression and decrease metastatic potential via regulating HIF-1α, VEGF and MMPs in SCC. Several therapeutic strategies, for example hyperbaric oxygen therapy, for changing oxygen conditions or specifically targeting hypoxic cells have been attempted. Unfortunately, these therapies have not been confirmed to be clinically beneficial.

Mitochondria play important roles in cellular energy metabolism and apoptosis. Alterations in respiratory activity and mtDNA mutations have been reported in various malignant tumors [40,41]. Cancer cells produce their energy through the glycolytic pathway under anaerobic conditions [40]. We targeted the differences of mitochondrial energy metabolism between normal and cancer cells, and hypothesized that improving hypoxic and aerobic conditions should be useful and important for cancer treatment. Although mitochondria proliferate independently from cancer cells [42], the speed of cancer cell division and proliferation is more likely faster than mitochondria under hypoxic conditions. Therefore, while cancer cells exhibit abnormal proliferation., the number of mitochondria decreases in cancer cells under hypoxic conditions, and mitochondrial dysfunction (the Warburg effect) results in avoiding apoptosis in tumor tissue. Apoptosis, a genetically encoded program for cell death that can be activated under physiological conditions, may be an important safeguard against tumor development [43]. Therefore, a current focus in cancer therapy research is improving understanding of apoptotic pathways and development of agents that target them [44]. We have also reported that an increased number of mitochondria induces apoptosis in sarcoma cells [45], and we speculate this phenomenon does not occur in normal tissue without cancer cell proliferation. In this study, we examined that transcutaneous CO2 inhibits SCC tumor growth in vivo by increasing the number of mitochondria and activating mitochondrial apoptosis by reducing intra-tumoral hypoxia.

We have previously shown that transcutaneous CO2 system causes absorption of CO2 and increase in O2 pressure in treated tissue, potentially causing an “Artificial Bohr Effect” [12]. CO2 therapy significantly decreases expressions of both HIF-1α and VEGF in human MFH, which suggests that CO2 therapy reduces hypoxia in the treated tumor tissue [9]. Based on these findings, we investigated whether making the environment of SCCs less hypoxic by using transcutaneous CO2 induces tumor cell apoptosis and suppresses lymphogenous metastasis to the regional lymph nodes by a mitochondrial pathway. In this study, we found that transcutaneous CO2 suppresses SCC growth by inducing apoptosis and significantly suppresses metastasis to lymph nodes by reducing intra-tumoral hypoxia and suppressing metastatic potential. These findings are consistent with our previous reports that transcutaneous CO2 alone significantly decreases tumor growth by inducing mitochondrial apoptosis in human MFH xenografts [14], and that transcutaneous CO2 decreases the incidence of lung metastasis of osteosarcoma by reducing local hypoxia [5]. Our findings strongly indicate that the mechanisms by which transcutaneous CO2 induces antitumor effects include suppressing metastasis of various malignant tumors and inducing tumor cell apoptosis, both mechanisms involving reduction of local hypoxia. However, whether decreasing the rate of metastasis is mediated by suppressing growth of the primary tumor or its ability to metastasize is not clear. Our future studies will focus on the investigation of lymphogenous metastatic factors.

It can be also considered that decreasing tumor growth results in reduced cancer cell viability and decreased micro-metastasis. We believe other mechanisms may mediate hypoxia-induced metastasis. Therefore, examining mobility or invasion in detail should be the focus of future studies.

Conclusions

In summary, this is the first report to show that transcutaneous CO2 suppresses growth of primary human SCC and their lymphogenous metastasis to the regional lymph nodes by making their environment less hypoxic and increasing mitochondrial apoptosis. Our present findings indicate that transcutaneous CO2 decreases the malignant potential of SCC with few side effects.

Supporting Information

Figure S1 The effect of transcutaneous CO2 on the metastatic potential of HSC-3. In an enlarged image of immunohistochemical staining, we observed that hypoxic condition (HIF-1α), abnormal excessive vascularization (VEGF) and metastatic potential (VEGF, MMP-2 and MMP-9) were decreased in CO2-treated cancer cells. (TIF)

Acknowledgments

We thank Minako Nagata, Maya Yasuda and Kyoko Tanaka for their expert technical assistance.

Author Contributions

Conceived and designed the experiments: DT TU TH. Performed the experiments: DT TU TH YI. Analyzed the data: DT TU TH. Contributed reagents/materials/analysis tools: TU. Wrote the paper: DT TU TH. Acknowledgments

References

1. Umeda M, Yokoo S, Komori T, Nishimatsu N, Shibuya Y, et al. (2001) Experimental Model Of Invasion And Metastasis By Orthotopic Transplantation Of Oral Squamous And Adenoid Cystic Carcinomas Into The Tongue Of Nude Mice. Br J Oral Maxillofac Surg 39: 376–380.
2. Layland MK, Sessions DG, Lenox J (2003) The Influence Of Lymph Node Metastasis In The Treatment Of Squamous Cell Carcinoma Of The Oral Cavity, Oropharynx, Larynx, And Hypopharynx: N0 Versus N+. Laryngoscope 113: 629–639.
3. Sun R, Zhang JG, Guo CB (2008) Establishment Of Cervical Lymph Node Metastasis Model Of Squamous Cell Carcinoma In The Oral Cavity In Mice. Chin Med J (Engl) 121: 1091–1095.
4. Kang PW, Gao Y, Que L, Sun J, Wang ZL (2013) Hypoxia-Inducible Factor-1alpha Overexpression Indicates Poor Clinical Outcomes In Tongue Squamous Cell Carcinoma. Exp Ther Med 5: 112–118.
5. Harada R, Kawanoto T, Urba T, Minoda M, Toda M, et al. (2013) Reoxygenation Using A Novel CO2 Therapy Decreases The Metastatic Potential Of Osteosarcoma Cells. Exp Cell Res 319: 1988–1997.
6. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, et al. (2002) Hypoxia-Inducible Factors HIF-1alpha And HIF-2alpha In Head And Neck Cancer: Relationship To Tumor Biology And Treatment Outcome In Surgically Resected Patients. Cancer Res 62: 2493–2497.
Transcutaneous Application of Carbon Dioxide to Oral SCC

7. Urhara M, Sano K, Ibeda H, Nonaka M, Aasahina I (2009) Hypoxia-Inducible Factor 1 Alpha In Oral Squamous Cell Carcinoma And Its Relation To Prognosis. Oral Oncol 45: 241-246.

8. Perez-Sayans M, Suarez-Fenaradja JM, Pilar GD, Barroso-Anqueria F, Gandara-Rey JM, al et (2011) Hypoxia-Inducible Factors In OSCC. Cancer Lett 313: 1-8.

9. Onishi Y, Kawamoto T, Urha T, Haru H, Fukase N, al et (2012) Transcutaneous Application Of Carbon Dioxide (CO2) Enhances Chemosen- sitivity By Reducing Hypoxia-Inducible Human Malignant Oral HistioCytoMy. Journal Of Cancer Science & Therapy 4: 174-181.

10. Resch KL, Just U (1994) [Possibilities And Limits Of CO2 Balneotherapy]. Wien Med Wochenschr 144: 45–50.

11. Hartmann BR, Bassenge E, Pittler M (1997) Effect Of Carbon Dioxide-Enriched Water And Fresh Water On The Cutaneous Microcirculation and Oxygen Tension In The Skin Of The Foot. Angiology 48: 337-343.

12. Sakai Y, Mima M, Oe K, Ueda Y, Koh A, al et (2011) A Novel System For Transcutaneous Application Of Carbon Dioxide Causing An "Artificial Bohr Effect" In The Human Body. Poss One 6: E24137.

13. Or E, Urha T, Sakai Y, Niikura T, Lee SY, et al (2011) The Effect Of Transcutaneous Application Of Carbon Dioxide (CO2) On Skeletal Muscle. Biochem Biophys Res Commun 407: 148–152.

14. Onishi Y, Kawamoto T, Urha T, Kishimoto K, Haru H, etc (2012) Transcutaneous Application Of Carbon Dioxide (CO2) Induces Mitochondrial Apoptosis In Human Malignant Fibrous HistioCytoMy In Vivo. Poss One 7: E91289.

15. Matsu T, Oka T, Ueda Y, Tamino M, Odahima S (1998) Isolation Of A Highly Metastatic Cell Line To Lymph Node In Human Oral Squamous Cell Carcinoma By Orthopic Implantation In Nude Mice. Oral Oncol 34: 253–256.

16. Okada Y, Ueno H, Katagiri M, Oneyama C, Shimomura K, et al (2010) Experimental Study Of Antiangiogenic Gene Therapy Targeting VEGF In Oral Cancer. Odontology 98: 52–59.

17. Yasuda A, Kondo S, Nagumo T, Tsukamoto M, Makadai Y, et al (2011) Anti-angiogenic Activity Of Deoxyadenosylcobalamin Against Human Oral Squamous Cell Carcinoma Cell Lines In Vitro And In Vivo. Oral Oncol 47: 334–339.

18. Yu M, Yan Y, Zou Q (2010) Decreased Copy Number Of Mitochondrial DNA Expression In Ewing's Sarcoma. Clin Chim Acta 411: 679–683.

19. Komatsubara H, Umeda M, Ojima Y, Minamikawa T, Komori T (2005) Hypoxia-Inducible Factor 1-Alpha Expression Correlates With Vascular Endothelial Growth Factor Gene Expression By Hypoxia-Inducible Factor 1. Mol Cell Biol 16: 4604–4613.

20. Liang X, Yang D, Hu J, Hao X, Gao J, et al (2008) Hypoxia Inducible Factor-Alpha Expression Correlates With Vascular Endothelial Growth Factor-C Expression And Lymphangiogenesis/Angiogenesis In Oral Squamous Cell Carcinoma. Anticancer Res 28: 1659–1666.

21. Shemirani B, Crowe DL (2002) Hypoxic Induction Of HIF-1alpha And VEGF Expression In Head And Neck Squamous Cell Carcinoma Lines Is Mediated By Stress Activated Protein Kinases. Oral Oncol 38: 251–257.

22. Sugiura T, Iinure Y, Matoski R, Iishi K, Takahashi M, et al (2009) VEGF-C And VEGF-D Expression Is Correlated With Lymphatic Vessel Density And Lymph Node Metastasis In Oral Squamous Cell Carcinoma: Implications For Use As A Prognostic Marker. Int J Oncol 34: 673–680.

23. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG (2008) Prognostic Significance Of Vascular Endothelial Growth Factor Protein Levels In Oral And Oropharyngeal Squamous Cell Carcinoma. J Clin Oncol 21: 2046–2052.

24. Yang NH, Wu KJ (2008) TWIST Activation By Hypoxia Inducible Factor-1 (HIF-1): Implications In Metastasis And Development. Cell Cycle 7: 2090–2096.

25. Teppo S, Sundquist E, Vered M, Parkkinen J, et al (2013) The Hypoxic Tumor Microenvironment Regulates Invasion Of Aggressive Oral Carcinoma Cells. Exp Cell Res 319: 376–389.

26. Comerford KM, Wallace JT, Karhausen J, Louis NA, Montalto MC, et al (2002) Hypoxia-Inducible Factor 1-Dependent Regulation Of The Multidrug Resistance (MDR1) Gene. Cancer Res 62: 3387–3394.

27. Miyazaki Y, Haru K, Kato O, Yamada Y, et al (2008) The Effect Of Hypoxic Microenvironment On Matrix Metalloproteinase Expression In Xenografts Of Human Oral Squamous Cell Carcinoma. Int J Oncol 32: 145–151.

28. Saab E, Tatemoto Y, Li D, Yamamoto T, Okuki T (2005) Mechanism Of HIF-1alpha-Dependent Suppression Of Hypoxia-Induced Apoptosis In Squamous Cell Carcinoma Cells. Cancer Sci 96: 394–402.

29. Forshyme JA, Jiang BH, Iyer NV, Agami F, Leung SW, et al (1996) Activation Of Vascular Endothelial Growth Factor Gene Transcription By Hypoxia-Inducible Factor 1. Mol Cell Biol 16: 4604–4613.

30. Liang X, Yang D, Hu J, Hao X, Gao J, et al (2008) Hypoxia Inducible Factor-Alpha Expression Correlates With Vascular Endothelial Growth Factor-C Expression And Lymphangiogenesis/Angiogenesis In Oral Squamous Cell Carcinoma. Anticancer Res 28: 1659–1666.

31. Sugiura T, Iinure Y, Matoski R, Iishi K, Takahashi M, et al (2009) VEGF-C And VEGF-D Expression Is Correlated With Lymphatic Vessel Density And Lymph Node Metastasis In Oral Squamous Cell Carcinoma: Implications For Use As A Prognostic Marker. Int J Oncol 34: 673–680.

32. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG (2008) Prognostic Significance Of Vascular Endothelial Growth Factor Protein Levels In Oral And Oropharyngeal Squamous Cell Carcinoma. J Clin Oncol 21: 2046–2052.

33. Yang NH, Wu KJ (2008) TWIST Activation By Hypoxia Inducible Factor-1 (HIF-1): Implications In Metastasis And Development. Cell Cycle 7: 2090–2096.

34. De Vicente JC, Fresno MF, Villalain L, Vega JA, Hernandez Vallejo G (2005) Expression And Clinical Significance Of Matrix Metalloproteinase-2 And Matrix Metalloproteinase-9 In Oral Squamous Cell Carcinoma. Oral Oncol 41: 283–293.

35. Qiao B, Johnson NW, Gao J (2010) Epithelial-Mesenchymal Transition In Oral Squamous Cell Carcinoma Triggered By Transforming Growth Factor-Beta Is Snail Family-Dependent And Correlates With Matrix Metalloproteinase-2 And -9 Expressions. Int J Oncol 37: 663–668.

36. Zhou CX, Gao Y, Johnson NW, Gao J (2010) Immunoexpression Of Matrix Metalloproteinase-2 And Matrix Metalloproteinase-9 In The Metastasis Of Squamous Cell Carcinoma Of The Human Tongue. Onc Lett 31: 383–389.

37. Tamamura R, Nagatsuka H, Siar CH, Taniati R, et al (2013) Comparative Analysis Of Basal Lamina Type IV Collagen Alpha Chains, Matrix Metalloproteinase-2 And -9 Expressions In Oral Dysplasia And Invasive Carcinoma. Acta Histochem 115: 113–119.

38. Patel BP, Shah NV, Shukla SN, Shah PM, Patel PS (2007) Clinical Significance Of MMP-2 And MMP-9 In Patients With Oral Cancer. Head Neck 29: 564–572.

39. Carew JS, Huang P (2002) Mitochondrial Defects In Cancer. Mol Cancer 1: 9.

40. Chatterjee A, Mambo E, Sudransky D (2006) Mitochondrial DNA Mutations In Human Cancer. Oncogene 25: 4663–4674.

41. Sagan L (1967) On The Origin Of Mitosing Cells. J Theor Biol 14: 253–274.

42. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, et al (1996) Vascular Endothelial Growth Factor Gene Transcription By Hypoxia-Inducible Factor 1. Mol Cell Biol 16: 4604–4613.

43. Qiao B, Johnson NW, Gao J (2010) Epithelial-Mesenchymal Transition In Oral Squamous Cell Carcinoma Triggered By Transforming Growth Factor-Beta Is Snail Family-Dependent And Correlates With Matrix Metalloproteinase-2 And -9 Expressions. Int J Oncol 37: 663–668.

44. Shemirani B, Crowe DL (2002) Hypoxic Induction Of HIF-1alpha And VEGF Expression In Head And Neck Squamous Cell Carcinoma Lines Is Mediated By Stress Activated Protein Kinases. Oral Oncol 38: 251–257.